Please Wait.....
Report
mRNA: Therapeutics and Global Markets
Market Research Report I 2025-09-10 I 131 Pages I BCC Research
Description
Report Scope
The report analyzes the global market for mRNA therapeutics. It includes global revenue ($ millions) for the base year of 2024, estimated data for 2025 and projected compound annual growth rates (CAGRs) through 2030. The report examines the different types of mRNA and their applications for therapeutic use. It also focuses on mRNA patents and clinical trials and examines the trends affecting the market during the forecast period. The report profiles the leading companies and their strategic alliances and partnerships. The report segments the global market into North America, Europe, Asia-Pacific (APAC) and the Rest of the World (RoW).
Report Includes
- 19 data tables and 71 additional tables
- An overview and analysis of the global markets for messenger RNA (mRNA)-based therapeutics
- Analyses of the global market trends, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
- Estimates of the size and revenue prospects for the global mRNA market, along with a market share analysis by disease type, indication, and region
- Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations and the impacts of macroeconomic variables
- Insights derived from Porter's Five Forces model, global supply chain and PESTLE analyses
- Patent analysis, featuring key granted and published patents
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings and consumer attitudes
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Moderna Inc., Pfizer Inc., BioNTech SE, Merck & Co., and Sanofi
Executive Summary
Summary:
The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable or slightly decline to $7.69 billion by the end of 2030, at a compound annual growth rate (CAGR) of -0.04% during the forecast period of 2025 to 2030.
Therapies using messenger ribonucleic acid, or mRNA, have immense potential for treating chronic diseases. Vaccines incorporating mRNA provide several advantages over DNA vaccines in manufacturing, distribution and safety. There is a demand for vaccines and treatments using mRNA because of their encouraging results in human clinical trials. The market is expanding due to increased clinical trials and the global proliferation of stem cell therapies. Governments, academic institutions and biotech and pharma companies are concentrating on detecting infectious and rare diseases. The global market for mRNA therapeutics market presents a multibillion-dollar opportunity for vaccines and other therapies.
COVID-19 mRNA-based vaccines are currently available, and research continues to find new methods for preventing and treating infections and illnesses. Essential for many bodily functions, mRNA instructs the body's cells to produce proteins. Essentially, mRNA participates in biological processes within our bodies to potentially treat diseases and stop infections.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Growth Factors
Emerging Technologies
COVID mRNA Vaccines
Regional Analysis
Conclusion
Chapter 2 Market Overview
Technology Background
Evolution of RNA Therapeutics
DNA Therapeutics vs. RNA Therapeutics
RNA Therapeutics
mRNA as Therapeutics
Regulatory Agency-Approved mRNA Vaccines
Porter's Five Forces Analysis
Potential for New Entrants
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of Substitute Products or Services
Industry Competition
Impact of U.S. Tariffs on the mRNA Therapeutics Market
Conclusion
Chapter 3 Market Dynamics
Overview
Market Drivers
Rising Numbers of Pandemics and Epidemics
Awareness of the Need for Vaccinations
Investments in mRNA Therapeutics Research
Market Restraints
Limitations of mRNA Vaccines
Production and Logistical Hurdles
Market Opportunities
Personalized Cancer Vaccines
Potential of mRNA Drugs to Treat Various Diseases
Chapter 4 Regulatory Landscape
Regulatory Scenario
Overview of Regulatory Bodies
Guidelines and Standards for mRNA Vaccines
Preclinical and Clinical Evaluation
Manufacturing and Post-Marketing Surveillance
Continual Monitoring and Risk Management
Chapter 5 Pipeline and Clinical Trial Analysis
Takeaways
mRNA Vaccines
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Breakdown by Disease Type
Takeaways
COVID mRNA Vaccines
Non-COVID mRNA Vaccines and Therapeutics
Market Breakdown by Indication
Cancer
Infectious Diseases
Rare Diseases
Others
Geographic Breakdown
Market Breakdown, by Region
Takeaways
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Emerging Technologies and Developments
Emerging Technologies in mRNA Therapeutics
Nanoparticles
Modified mRNA
Automated mRNA Synthesis Kits
Bio Platforms
Artificial Intelligence
AI Developments at mRNA Therapeutics Companies
Chapter 8 Patent Analysis
Takeaways
mRNA Publications
List of Patents
Chapter 9 Sustainability in the mRNA Therapeutics Industry: An ESG Perspective
Sustainability in the mRNA Therapeutics Industry
ESG Risk Ratings
ESG Performance Analysis
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC Research
Chapter 10 Competitive Intelligence
Takeaways
Leading Companies in the mRNA Therapeutics Market, 2024
Strategic Analysis
Collaborations and Partnerships
Regulatory Approvals
Clinical Trials Data
Funding and Grants
Chapter 11 Appendix
Methodology
Abbreviations
Sources
Company Profiles
ARCTURUS THERAPEUTICS INC.
ASTRAZENECA
BIOCINA
BIONTECH SE
CUREVAC SE
ETHRIS GMBH
GENNOVA BIOPHARMACEUTICALS LTD.
GSK PLC.
IMMORNA (HANGZHOU) BIOTECHNOLOGY CO. LTD.
MERCK & CO. INC.
MODERNA INC.
NUTCRACKER THERAPEUTICS INC.
PFIZER INC.
PROVIDENCE THERAPEUTICS
SANOFI
STRAND THERAPEUTICS INC.
List of Tables
Summary Table : Global Market for mRNA Therapeutics, by Disease, Through 2030
Table 1 : Evolution of RNA Therapeutics
Table 2 : Approved mRNA Vaccines, 2025
Table 3 : Pandemics of the 21st Century
Table 4 : Status of Clinical Trials for mRNA-based Drugs, 2025
Table 5 : Clinical Trials for mRNA Vaccines, 2025
Table 6 : Global Market for mRNA Therapeutics, by Disease Type, Through 2030
Table 7 : Properties of the BNT162b2 Vaccine
Table 8 : Properties of the mRNA-1273 Vaccine
Table 9 : Properties of the CVnCoV Vaccine
Table 10 : Global Market for COVID mRNA Therapeutics, by Region, Through 2030
Table 11 : Global Market for Non-COVID mRNA Vaccines and Therapeutics, by Region, Through 2030
Table 12 : Global Cancer-Related Deaths, by Cancer Type, Through 2030
Table 13 : Global Market for mRNA Therapeutics, by Region, Through 2030
Table 14 : North American Market for mRNA Therapeutics, by Disease Type, Through 2030
Table 15 : European Market for mRNA Therapeutics, by Disease Type, Through 2030
Table 16 : Asia-Pacific Market for mRNA Therapeutics, by Disease Type, Through 2030
Table 17 : RoW Market for mRNA Therapeutics, by Disease Type, Through 2030
Table 18 : Organizations with the Most Published mRNA Patents
Table 19 : Patents for mRNA Therapeutics, 2025
Table 20 : Patents Related to mRNA Vaccines for Infectious Diseases, 2025
Table 21 : Patents Related to mRNA Vaccines for Cancer Treatment, 2025
Table 22 : Patents Focused on mRNA Delivery and Modification
Table 23 : Focus Areas in ESG Metrics
Table 24 : ESG Rankings for Major mRNA Therapeutics Companies, 2025*
Table 25 : ESG: Environmental Overview
Table 26 : ESG: Social Factors Overview
Table 27 : ESG: Governance Overview
Table 28 : Collaborations and Partnerships in the mRNA Therapeutics Market, 2023-2025
Table 29 : Regulatory Approvals in the mRNA Therapeutics Industry, 2023-2025
Table 30 : Clinical Trial Data in the mRNA Therapeutics Market, 2022-2025
Table 31 : Funding and Grants in the mRNA Therapeutics Market, 2023-2025
Table 32 : Abbreviations Used in this Report
Table 33 : Arcturus Therapeutics Inc.: Company Snapshot
Table 34 : Arcturus Therapeutics Inc.: Financial Performance, FY 2023 and 2024
Table 35 : Arcturus Therapeutics Inc.: Product Pipeline
Table 36 : Arcturus Therapeutics Inc.: News/Key Developments, 2024-2025
Table 37 : AstraZeneca: Company Snapshot
Table 38 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 39 : AstraZeneca: Product Pipeline
Table 40 : AstraZeneca: News/Key Developments, 2025
Table 41 : BioCina: Company Snapshot
Table 42 : BioCina: Product Portfolio
Table 43 : BioCina: News/Key Developments, 2023-2025
Table 44 : BioNTech SE: Company Snapshot
Table 45 : BioNTech SE: Financial Performance, FY 2023 and 2024
Table 46 : BioNTech SE: Product Pipeline
Table 47 : BioNTech SE: News/Key Developments, 2023-2024
Table 48 : CureVac SE: Company Snapshot
Table 49 : CureVac SE: Financial Performance, FY 2023 and 2024
Table 50 : CureVac SE: Product Pipeline
Table 51 : CureVac SE: News/Key Developments, 2024-2025
Table 52 : Ethris GmbH: Company Snapshot
Table 53 : Ethris GmbH: Product Pipeline
Table 54 : Ethris GmbH: News/Key Developments, 2023-2025
Table 55 : Gennova Biopharmaceuticals Ltd.: Company Snapshot
Table 56 : Gennova Biopharmaceuticals Ltd.: Product Portfolio
Table 57 : Gennova Biopharmaceuticals Ltd.: News/Key Developments, 2023
Table 58 : GSK PLC: Company Snapshot
Table 59 : GSK PLC: Financial Performance, FY 2023 and 2024
Table 60 : GSK PLC: Product Pipeline
Table 61 : GSK PLC: News/Key Developments, 2024
Table 62 : Immorna Biotechnology Co. Ltd.: Company Snapshot
Table 63 : Immorna Biotechnology Co. Ltd.: Product Pipeline
Table 64 : Immorna Biotechnology Co. Ltd: News/Key Developments, 2024-2025
Table 65 : Merck & Co. Inc.: Company Snapshot
Table 66 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 67 : Merck & Co. Inc.: Product Pipeline
Table 68 : Merck & Co. Inc.: News/Key Developments, 2023
Table 69 : Moderna Inc.: Company Snapshot
Table 70 : Moderna Inc.: Financial Performance, FY 2023 and 2024
Table 71 : Moderna Inc.: Product Pipeline
Table 72 : Moderna Inc.: News/Key Developments, 2024-2025
Table 73 : Nutcracker Therapeutics Inc.: Company Snapshot
Table 74 : Nutcracker Therapeutics Inc.: Product Portfolio
Table 75 : Nutcracker Therapeutics Inc.: News/Key Developments, 2024-2025
Table 76 : Pfizer Inc.: Company Snapshot
Table 77 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 78 : Pfizer Inc.: Product Portfolio
Table 79 : Pfizer Inc.: News/Key Developments, 2024
Table 80 : Providence Therapeutics: Company Snapshot
Table 81 : Providence Therapeutics: Product Pipeline
Table 82 : Providence Therapeutics: News/Key Developments, 2022-2024
Table 83 : Sanofi: Company Snapshot
Table 84 : Sanofi: Financial Performance, FY 2023 and 2024
Table 85 : Sanofi: Product Pipeline
Table 86 : Sanofi: News/Key Developments, 2024-2025
Table 87 : Strand Therapeutics Inc.: Company Snapshot
Table 88 : Strand Therapeutics Inc.: Product Pipeline
Table 89 : Strand Therapeutics Inc.: News/Key Developments, 2024-2025
List of Figures
Summary Figure : Global Market Shares of mRNA Therapeutics, by Disease, 2024
Figure 1 : Porter's Five Forces Analysis
Figure 2 : Snapshot of Market Dynamics
Figure 3 : Factors Responsible for the Rising Number of Pandemics
Figure 4 : Clinical Trials for mRNA Vaccines, by Disease Indication, 2023-2025
Figure 5 : mRNA Vaccine Candidates in Clinical Trials, by Phase, 2023-2025
Figure 6 : mRNA Vaccine Candidates in Clinical Trials, by Study Type, 2023-2025
Figure 7 : mRNA Vaccine Candidates in Clinical Trials, by Funding Source, 2023-2025
Figure 8 : Global Market Shares of mRNA Therapeutics, by Disease Type, 2024
Figure 9 : Global Cancer-Related Deaths, by Cancer Type, 2000-2030
Figure 10 : Global Market Shares of mRNA Therapeutics, by Region, 2024
Figure 11 : Emerging Technologies in mRNA Therapeutics
Figure 12 : Patents on mRNA Therapeutics, 2010-2022
Figure 13 : Patent Shares on mRNA Therapeutics, by Patent Classification, 2010-2021
Figure 14 : Published mRNA-based Patents, 2019-2022
Figure 15 : How a Strong ESG Proposition Can Benefit Businesses
Figure 16 : Moderna's mRNA Therapeutics Product Pipeline, by Clinical Phase, 2025
Figure 17 : BioNTech's mRNA Therapeutics Product Pipeline, by Clinical Phase, 2025
Figure 18 : Arcturus Therapeutics Inc: Revenue Shares, by Business Unit, FY 2024
Figure 19 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
Figure 20 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
Figure 21 : BioNTech SE: Revenue Shares, by Region/Country, FY 2024
Figure 22 : GSK PLC: Revenue Shares, by Business Unit, FY 2024
Figure 23 : GSK PLC: Revenue Shares, by Region/Country, FY 2024
Figure 24 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 25 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 26 : Moderna Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 27 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 28 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 29 : Sanofi: Revenue Shares, by Country/Region, FY 2024
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security